目的探讨氯沙坦和贝那普利联合治疗早期糖尿病肾病的临床效果与安全性。方法选择36例内分泌科门诊及住院病例,随机平分为治疗组和对照组,治疗组应用氯沙坦和贝那普利联合治疗,对照组单用贝那普利治疗,比较两组疗效和不良反应。结果 2组患者治疗前的各项检查指标均无显著性差异,2组治疗后24h蛋白尿(UAE)、血肌酐(Cr)和尿素氮(BUN)的浓度与治疗前比较,均显著下降,差异有统计学意义(P<0.05),但治疗组下降幅度更大,治疗后与对照组相比,差异有统计学意义(P<0.05),说明治疗组疗效优于对照组。各组间不良反应无统计学差异(P>0.05)。结论氯沙坦和贝那普利联用治疗早期糖尿病肾病能明显提高疗效,而且耐受性和安全性较好,值得推广应用。 Objective To investigate the clinical efficacy and safety of losartan and benazepril in the treatment of early diabetic nephropathy. Methods 36 cases of endocrinology outpatient and inpatient cases were randomly divided into treatment group and control group. The treatment group was treated with losartan and benazepril. The control group was treated with benazepril alone. The curative effect and adverse effects in both groups were compared reaction. Results There was no significant difference between the two groups before treatment. The proteinuria (UAE), serum creatinine (Cr) and blood urea nitrogen (BUN) in two groups after treatment were significantly lower than those before treatment The difference was statistically significant (P <0.05), but the treatment group decreased more, compared with the control group after treatment, the difference was statistically significant (P <0.05), indicating that the treatment group than the control group. Adverse reactions among the groups showed no significant difference (P> 0.05). Conclusion Losartan and benazepril combined treatment of early diabetic nephropathy can significantly improve the efficacy, and tolerance and safety is good, it is worth promoting the application.